Sawsan Rashdan, MD
Medical Oncology · Dallas, TXNPI 1316173610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,482 of the $31,568 with a category attached, or 87.1%. AstraZeneca accounts for 66.2% of it on its own, with 9 other manufacturers making up the rest.
Across 31 payments — averaging $1018.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$21K
- Daiichi Sankyo Inc.$3K
- Amgen$2K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- G1 Therapeutics, Inc.$2K
- plus $923 from 4 others
Across 90 payments — averaging $332,063 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$29.2M
- Janssen Research & Development, LLC$228K
- Daiichi Sankyo Inc.$131K
- E.r. Squibb & Sons, L.L.C.$123K
- Novocure Inc.$116K
- Regeneron$62K
What the payments were for
- Consulting fees$27,48287%
- Speaking & faculty fees$2,2507%
- Travel & lodging$1,4405%
- Food & beverage$3821%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $20,913 |
| Daiichi Sankyo Inc. | 2 | $3,083 |
| Amgen | 1 | $2,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,575 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,575 |
| G1 Therapeutics, Inc. | 1 | $1,500 |
| Catalyst Pharmaceuticals, Inc. | 2 | $786 |
| Eli Lilly | 1 | $105 |
| Merck | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,568 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $11,542 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $435 |
| Prochlorperazine Maleate | 30 | $306 |
| Mirtazapine | 11 | $144 |
| Dexamethasone | 26 | $128 |
| Ondansetron Hcl | 21 | $112 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.